How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
March 23, 2017 |
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma
The official roll-out of Sustainability and Transformation Plans (STPs) in April will herald the dawn of a new era for NHS commissioning as the old divisions between primary and secondary care are finally swept away.
Key changes will include a reduction in the number of commissioners. For example, the Birmingham and Solihull STP plans to merge its three CCGs; while Lancashire and South Cumbria propose a single health and well-being board.
There will be new roles for the remaining CCGs, which will be empowered to commission services across the entire care pathway – from diagnosis through to end of life care – following new co-commissioning arrangements with NHS England.
Each of the 44 STPs will adopt a different approach to commissioning services, based on local needs and conditions. NHS England’s strategic framework for specialised services has called for an area-by-area approach, and a move away from the ‘binary’ system where services were either nationally or locally commissioned.
Wilmington Healthcare has been following the progress of all the 44 STPs in great detail, via its tracker system for the past six months. Pharma needs to drill down into the individual footprints in a similar level of detail in order to get to grips with STPs’ priorities and objectives, both top line and therapeutic, and obtain budgetary information and population statistics. It also needs to find out information, such as the burden of diseases in individual areas, and the key specialists.
To clarify its approach, pharma needs to think about the service now:
1. Which provider incurs the cost of delivering the service?
2. What are all the inputs currently required to deliver the service, including staff, premises, materials, medicines, training and travel?
3. Which commissioner currently pays for the service and what type of contract and tariff is used?
4. What is currently charged to the commissioner for buying the service?
Pharma also needs to think about the service of the future:
Which provider will incur the future costs of delivering the service? As well as looking at how costs are going to change, think about who will incur these costs.
What model is the provider working to – e.g. are they an Accountable Care Organisation (ACO) working on an outcomes-based contract built up from a capitated budget?
Which commissioners will pay for the new service and what will be charged to them? What will be the difference for commissioners after the service change?
Are there other consequences of a service change in terms of costs incurred to the NHS? For example, might your product reduce hospital admissions – is it given less frequently than competitors, or orally instead of by infusion?
Can the provider realise these savings through their model e.g. an ACO will look at system wide costs and may see an investment in drug prescribing as an opportunity to change the pathway of care to a more cost-effective community based service.
Pharma needs to understand how new patient pathways will work in the individual STPs, from diagnosis to death, and define how its products will fit into those pathways and really make a difference. To achieve this, it will need versatile customer-facing teams who are comfortable working with a variety of stakeholders, many of whom they may have had limited or no contact with in the past – such as local authorities, charities and patient groups – as well as clinicians across a wide spectrum of NHS services and particularly in CCGs and new much larger provider ACOs.
Ends
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
A new vision for tackling key illnesses
Steve How and Oli Hudson, of Wilmington Healthcare, explore the NHS Long-term Plan’s strategy for delivering more preventative, joined-up services for major health conditions
Spotlight on innovation at life sciences forum
Paul Midgley, of Wilmington Healthcare, takes a look at the forthcoming HSJ Life Sciences Forum, where the NHS and industry will unite to discuss challenges and explore innovative solutions
GPs will play a pivotal role in integrated care
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explain how the new GP contract will shape local joined-up systems
What role for pharma in helping to deliver integrated care?
Steve How and Paul Midgley, of Wilmington Healthcare, explore how pharma can support local health economies in providing joined-up, holistic services
Winners of the HSJ Partnership Awards 2019 unveiled
The winners of the HSJ Partnership Awards 2019 were announced on 20 March at a prestigious black-tie awards ceremony at Park Plaza, Westminster.
Putting disease prevention on a par with cure
Steve How and Paul Midgley, of the Wilmington Healthcare Consulting Team, explore how the NHS is taking an increasingly holistic approach to care
What does the new NHS plan mean for pharma?
Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of the NHS Long-term Plan
HSJ Partnership Awards 2019 shortlist announced
The finalists for the HSJ Partnership Awards have been announced today ahead of a prestigious black-tie dinner awards ceremony at Park Plaza, Westminster Bridge on 20 March 2019.
Healthcare excellence celebrated at 2018 HSJ Awards
Thousands of healthcare professionals were in attendance, all eager to scoop one of the coveted prizes from the world’s largest healthcare awards programme.
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry